SHMT1 Polymorphism in Parkinson's Disease,

Parkinson Disease (PD) is the most common movement disorder and represents the second most common degenerative disease of the central nervous system . SHMT has been shown to be associated with various...

Lead sponsor: Assiut University•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Effat a Tony, MD

CONTACT

+201097330309 effattony@aun.edu.eg

abeer a tony, MD

CONTACT

+201005389084 abeer.tony@aswu.edu.eg

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment80

Start dateJan 2021

Last updatedJun 2, 2021

Condition

Study the Role of SHMT1 Polymorphism in Parkinson Disease

Locations shown

Effat abdelhady tony

Asyut

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 2, 2021Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions